Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News:
Median Technologies (Paris:ALMDT):
Total number of shares
Number of real voting rights*
Theoritical number of voting rights*
(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF’s General Regulations
About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). For more information: www.mediantechnologies.com
Head of Corporate Communications
+33 6 10 93 58 88
Press – ALIZE RP
+33 6 64 18 99 59
Investors – ACTIFIN
+33 1 56 88 11 11